Metformin and Fatty Liver: Evidence and UK Guidance

Metformin and fatty liver disease are closely linked in clinical practice, as many people living with type 2 diabetes also have metabolic dysfunction-associated steatotic liver disease (MASLD). Metformin is not licensed specifically for fatty liver, but its ability to reduce insulin resistance and hepatic glucose production may offer indirect liver benefits. This article explains how fatty liver develops, what the evidence says about metformin's role, who is most likely to be prescribed it in the UK, what side effects to watch for, and which lifestyle changes can support liver health alongside medication.

What is fatty liver disease and how does it develop?

Fatty liver disease occurs when excess fat accumulates in liver cells, impairing function; MASLD, the preferred term for non-alcohol-related cases, is closely linked to obesity, type 2 diabetes, and insulin resistance.

Fatty liver disease is a condition in which excess fat accumulates within liver cells, impairing normal liver function over time. The two main forms are alcohol-related fatty liver disease (ARLD) and metabolic dysfunction-associated steatotic liver disease (MASLD), the latter being the term now preferred by international liver societies over the older label non-alcoholic fatty liver disease (NAFLD).^[1][11] You may still encounter the NAFLD and NASH labels in older NHS letters or clinic correspondence; they refer to the same conditions. MASLD is closely linked to obesity, type 2 diabetes, insulin resistance, and raised triglyceride levels.

In MASLD, the liver becomes overloaded with fatty acids, partly because insulin resistance drives excess fat release from adipose tissue and promotes fat synthesis within the liver itself. For most people, the condition begins as simple steatosis (fat accumulation without significant inflammation), but in a proportion it progresses to metabolic dysfunction-associated steatohepatitis (MASH), where inflammation and liver cell injury occur alongside the fat deposits.

Without intervention, a minority of people with MASH develop fibrosis (scarring), which can advance to cirrhosis and, in some cases, liver failure or hepatocellular carcinoma. NICE guidance (NG49) notes that MASLD is increasingly common in the UK, with higher rates among people living with obesity or type 2 diabetes.^[2][3] Early identification through liver function tests, ultrasound, and non-invasive fibrosis scoring tools is therefore an important part of primary care assessment.

In primary care, NICE NG49 recommends using the FIB-4 index or the NAFLD Fibrosis Score as initial tools to assess the likelihood of significant fibrosis.^[2][3] Where these suggest intermediate or high risk, an enhanced liver fibrosis (ELF) test may be used to guide decisions about referral to hepatology. If advanced fibrosis is suspected, a specialist hepatology opinion should be sought promptly.

Can metformin help with fatty liver disease?

Metformin is not licensed for fatty liver disease, but by reducing insulin resistance and hepatic glucose production it may indirectly reduce liver fat in people who also have type 2 diabetes.

Metformin is not currently licensed or recommended by NICE specifically for the treatment of fatty liver disease, but it is widely used in people who have both type 2 diabetes and MASLD, and its metabolic effects may offer indirect benefit to the liver.^[2][3] Metformin belongs to the biguanide class of medicines and works primarily by reducing hepatic glucose production (gluconeogenesis) and improving peripheral insulin sensitivity, both of which are central drivers of fat accumulation in the liver.

By lowering circulating insulin levels and reducing the liver's own glucose output, metformin addresses two of the key mechanisms that promote hepatic steatosis. Some researchers have proposed that metformin also activates AMP-activated protein kinase (AMPK), an enzyme that suppresses fat synthesis and promotes fatty acid oxidation within liver cells, though this is considered a proposed rather than definitively established mechanism.^[7][22]

It is important to note that any benefit metformin may offer to the liver is considered secondary to its primary role in glycaemic management. Clinicians in the UK prescribe metformin for type 2 diabetes in line with NICE guidance (NG28), and decisions about its use are based on a patient's overall metabolic profile rather than a fatty liver diagnosis alone. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online consultations, with prescriber review and pharmacist support, where a range of metabolic health options may be considered where clinically appropriate.

What does the evidence say about metformin and liver health?

Evidence is mixed; metformin modestly reduces ALT levels but has not consistently improved liver histology, and international guidelines do not recommend it as a primary treatment for MASLD.

The evidence on metformin and fatty liver disease is mixed, and no robust clinical trial has established it as an effective standalone treatment for MASLD or MASH. Several small randomised controlled trials and meta-analyses have examined liver enzyme levels, liver fat content measured by imaging, and histological outcomes (liver biopsy findings) in people taking metformin. Results have generally shown modest reductions in alanine aminotransferase (ALT) levels, a marker of liver inflammation, but improvements in liver histology, particularly in fibrosis and ballooning injury, have been inconsistent.

A Cochrane systematic review examining metformin in non-alcoholic fatty liver disease concluded that, while the drug appeared safe in this population, there was insufficient evidence to support its use specifically for liver disease outcomes. International liver disease guidelines, including those from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), similarly do not recommend metformin as a primary treatment for MASLD or MASH, noting that weight loss and lifestyle change remain the most evidence-based interventions.^[11]

In people with type 2 diabetes and coexisting MASLD, however, metformin remains a first-line agent because its glycaemic benefits are well established and improving blood glucose control itself reduces hepatic fat load. More recent research interest has shifted towards GLP-1 receptor agonists and, in the UK, tirzepatide (Mounjaro), which is MHRA-authorised both for type 2 diabetes and for chronic weight management, and which has shown effects on liver fat in clinical trial imaging substudies.^[12] The evidence base continues to evolve, and patients should discuss the most current options with their GP or specialist.

Who is most likely to be prescribed metformin for fatty liver in the UK?

People with type 2 diabetes and coexisting MASLD are most likely to receive metformin, as NICE NG28 recommends it as first-line diabetes treatment rather than for fatty liver alone.

In the UK, metformin is most likely to be prescribed to people who have type 2 diabetes alongside fatty liver disease, rather than to those with fatty liver disease alone. NICE guidance (NG28) recommends offering metformin as the first-line pharmacological treatment for type 2 diabetes in adults at diagnosis, unless it is contraindicated or not tolerated, and it is in this context that many people with MASLD will encounter it.^[5][6]

People most likely to be in this group include those with:

• Type 2 diabetes, where insulin resistance is a shared driver of both conditions

• Raised liver enzymes (ALT or AST) identified incidentally on blood tests, prompting further investigation

• Metabolic syndrome, characterised by central obesity, raised triglycerides, low HDL cholesterol, and hypertension

• Polycystic ovary syndrome (PCOS), where metformin is sometimes used off-label to improve insulin sensitivity

Metformin is contraindicated in people with an eGFR below 30 ml/min/1.73m², as the risk of lactic acidosis is unacceptably increased at this level of kidney impairment. For people with an eGFR between 30 and 45 ml/min/1.73m², the dose should be reviewed and more frequent monitoring of kidney function is recommended, in line with NG28 and the metformin SmPC. Metformin is also temporarily withheld around procedures involving iodinated contrast media.

People with advanced liver disease or cirrhosis may not be suitable candidates, as hepatic impairment can also increase the risk of lactic acidosis. Excessive alcohol intake and acute conditions that cause dehydration or sepsis are additional risk factors for lactic acidosis and should be discussed with your prescriber. A specialist hepatology opinion is advisable in those with established or suspected advanced fibrosis.

If non-invasive tests in primary care suggest intermediate or high risk of significant fibrosis, your GP may arrange an ELF test and, where appropriate, refer you to a hepatology specialist in line with NICE NG49.

Your GP is the appropriate first point of contact if you have been told you have a fatty liver and are wondering whether metformin or another medicine might be relevant to your situation.

What side effects should you watch for when taking metformin?

Gastrointestinal effects such as nausea and diarrhoea are most common; lactic acidosis is rare but serious, and long-term use can cause vitamin B12 deficiency requiring monitoring.

Metformin is generally well tolerated, but gastrointestinal side effects are the most commonly reported, particularly when treatment is first started or the dose is increased. These include nausea, diarrhoea, abdominal discomfort, and a metallic taste in the mouth. Taking metformin with or after food and starting at a low dose with gradual titration can help reduce these effects. Modified-release (MR) formulations are sometimes better tolerated than standard-release tablets.

Some people taking metformin develop vitamin B12 deficiency over time, as the drug can impair B12 absorption in the gut.^[15][16] NICE NG28 advises checking B12 levels if symptoms of deficiency are present, such as fatigue, tingling in the hands or feet, anaemia, or cognitive changes, and recommends considering periodic monitoring in people at risk of deficiency who are on long-term metformin. If you develop any of these symptoms, speak to your GP.

Lactic acidosis is a rare but serious complication associated with metformin, most likely to occur in people with significant kidney impairment, liver failure, severe infection, dehydration, or excessive alcohol intake. Symptoms include muscle pain, weakness, difficulty breathing, stomach discomfort, and feeling cold. If you experience these symptoms, seek urgent medical attention by calling 999 or going to your nearest A&E.

Suspected side effects from metformin can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This reporting helps the MHRA monitor the safety of medicines in real-world use. If you have concerns about a side effect that is not urgent, contact your GP or call NHS 111 for advice. Metformin does not typically cause hypoglycaemia (low blood sugar) when used alone, which is one of its advantages over some other diabetes medicines.

What other lifestyle changes can support a fatty liver alongside metformin?

Losing 7 to 10 per cent of body weight, following a Mediterranean-style diet, and completing at least 150 minutes of moderate exercise weekly are the most effective interventions for MASLD.

Weight loss through diet and increased physical activity remains the most effective intervention for fatty liver disease, and lifestyle change should underpin any pharmacological treatment. Evidence reviewed in NICE NG49 indicates that losing 7 to 10 per cent of body weight can significantly reduce liver fat, improve liver enzyme levels, and in some cases reverse early fibrosis. Even modest weight loss of 3 to 5 per cent can reduce hepatic steatosis.

Key lifestyle measures recommended for people with MASLD include:

• Dietary change: A Mediterranean-style diet, rich in vegetables, legumes, wholegrains, fish, and olive oil, and low in ultra-processed foods, refined sugars, and saturated fat, is associated with reduced liver fat and improved metabolic markers.

• Alcohol reduction: Even in MASLD (which is not caused by alcohol), reducing alcohol intake supports liver recovery and reduces the additional burden on liver cells. Excessive alcohol intake also increases the risk of lactic acidosis in people taking metformin.

• Physical activity: Both aerobic exercise (such as brisk walking, cycling, or swimming) and resistance training have been shown to reduce liver fat independently of weight loss.^[20][21] The UK Chief Medical Officers' guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults.^[18][19]

• Avoiding hepatotoxic substances: Some over-the-counter supplements and herbal remedies can be harmful to the liver. Always inform your GP or pharmacist of any supplements you are taking.

If you develop symptoms that may suggest advanced or decompensated liver disease, such as yellowing of the skin or eyes (jaundice), swelling of the abdomen, confusion, or vomiting blood, seek urgent assessment via your GP or urgent care without delay.

For people with type 2 diabetes and MASLD, optimising blood glucose control through a combination of metformin, lifestyle change, and, where appropriate, additional medicines prescribed by a clinician, offers the best chance of slowing disease progression. Regular monitoring of liver function, kidney function, and HbA1c through your GP is an important part of long-term management.

Scientific References

1. Understanding the evolving nomenclature of steatotic liver disease.
2. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
3. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49) — full guideline PDF.
4. Testing for advanced liver fibrosis — NICE QS152.
5. Type 2 diabetes in adults: management (NG28).
6. Initial medicines — Type 2 diabetes in adults: management (NG28).
7. Metformin hydrochloride | Drugs — BNF — NICE.
8. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.
9. Diabetes drugs for nonalcoholic fatty liver disease.
10. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with NAFLD/NASH: systematic review and meta-analysis of randomized controlled trials.
11. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease.
12. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
13. Metformin 500 mg film-coated tablets — Summary of Product Characteristics.
14. Metformin hydrochloride 750 mg prolonged-release tablets — Summary of Product Characteristics.
15. What ultimately underlies vitamin B12 and folate deficiency in subjects treated with biguanides?.
16. Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk.
17. Vitamin B12 deficiency in over 16s: diagnosis and management (NG239).
18. Physical activity guidelines: UK Chief Medical Officers' report.
19. UK Chief Medical Officers' physical activity guidelines (full text).
20. Structured Exercise Interventions and Hepatic-Metabolic Outcomes in Adults with MASLD: A Narrative Review of Randomized Controlled Trials.
21. Exercise improves surrogate measures of liver histological response in metabolic dysfunction-associated steatotic liver disease.
22. A Comprehensive Review of Metabolic Dysfunction-Associated Steatotic Liver Disease: Its Mechanistic Development Focusing on Methylglyoxal and Counterbalancing Treatment Strategies.

Frequently Asked Questions